Scientists test new mRNA cancer vaccine in patients who have run out of options
NCT ID NCT07245901
Summary
This early-stage clinical trial is testing a new personalized mRNA vaccine designed to teach the immune system to attack a specific protein found in a patient's tumor cells. The vaccine is given in combination with an existing immunotherapy drug (anti-PD-1) to boost the body's cancer-fighting response. The study will enroll about 60 adults with advanced solid tumors (like pancreatic, breast, or lung cancer) who have not responded to standard treatments, first to find a safe dose and then to see if the combination can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.